Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
2.040
-0.070 (-3.32%)
Jun 5, 2025, 10:20 AM - Market open

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.7510.012.370.020.01
Research & Development
1.772.241.570.830.13
Operating Expenses
12.5112.243.940.850.14
Operating Income
-12.51-12.24-3.94-0.85-0.14
Interest Expense
--4.34-1.64--
Interest & Investment Income
0.060.05---
EBT Excluding Unusual Items
-12.46-16.53-5.59-0.85-0.14
Other Unusual Items
---7.49--
Pretax Income
-12.46-16.53-13.07-0.85-0.14
Net Income
-12.46-16.53-13.07-0.85-0.14
Net Income to Common
-12.46-16.53-13.07-0.85-0.14
Shares Outstanding (Basic)
30302727-
Shares Outstanding (Diluted)
30302727-
Shares Change (YoY)
9.13%8.18%1.77%--
EPS (Basic)
-0.41-0.56-0.48-0.03-
EPS (Diluted)
-0.41-0.56-0.48-0.03-
EBIT
-12.51-12.24-3.94-0.85-0.14
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q